Anti-Venom Market Report 2023: Growth, Trends and Industry Forecast 2028
IMARC Group, a leading market research company, has recently releases report titled “Anti-Venom Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2028.” The study provides a detailed analysis of the industry, including the global anti-venom industry trends, share, size, and growth forecasts. The report also includes competitor and regional analysis and highlights the latest advancements in the market.
Report Highlights
How big is the Anti-Venom market?
| Report Attributes | Details |
| Market Size in 2022 | US$ 1,096.1 Million |
| Market Forecast in 2028 | US$ 1,644.9 Million |
| Growth rate (2023 to 2028) | CAGR of 6.7% |
| Base Year of the Analysis | 2022 |
| Forecast Period | 2023-2028 |
Anti-venom,
also known as antivenin or anti-venom serum, is a medical treatment to
counteract the life-threatening effects of venomous animal bites and stings. It
is a specific type of antitoxin that contains antibodies targeted against the
toxins present in the venom of creatures, such as snakes, spiders, scorpions,
and marine animals. It can neutralize the effects of venom, preventing the
progression of symptoms and potentially saving lives. It is administered in
various animals, such as horses and sheep, to develop antibodies against the
venom, which are extracted and purified to create the final anti-venom product.
It also reduces the need for more extensive and costly medical interventions,
such as surgery or mechanical ventilation.
Request for a sample copy of this report: https://www.imarcgroup.com/anti-venom-market/requestsample
What are the growth prospects and trends in the anti-venom industry?
At present,
the increasing awareness about the timely administration of anti-venom
components, as it can significantly improve the chances of a full recovery and
minimize long-term complications, represents one of the crucial factors
impelling the growth of the market.
Besides
this, the rising utilization of anti-venoms in research operations to
understand venomous creatures and their toxins is propelling the growth of the
market. In addition, pharmaceutical companies and research institutions are
investing in innovative technologies, such as recombinant deoxyribonucleic acid
(DNA) technology and nanotechnology, to develop safer and more efficient
anti-venom therapies. Apart from this, governing agencies of various countries
and non-governmental organizations (NGOs) are focusing on raising awareness,
improving healthcare infrastructure, and ensuring the availability of
affordable anti-venom treatments, especially in regions wherein snakebite
incidents are prevalent.
Additionally,
rising collaborations and partnerships between pharmaceutical companies,
research institutions, and healthcare organizations to create advanced
anti-venom therapies are strengthening the growth of the market. Moreover, the
increasing imposition of stringent guidelines and standards for the production
and distribution of anti-venom products to ensure their safety and efficacy is
currently bolstering the growth of the market.
Explore Full Report with Table of Contents: https://www.imarcgroup.com/anti-venom-market
What is included in market segmentation?
The report has segmented the market into the following categories:
Breakup by Species:
- Snake
- Scorpion
- Spider
- Others
Breakup by Anti-venom Type:
- Polyvalent Anti-venom
- Monovalent Anti-venom
Breakup by Mode of Action:
- Cytotoxic
- Neurotoxic
- Haemotoxic
- Cardiotoxic
- Myotoxic
- Others
Breakup by End User:
- Hospitals
- Clinics
- Ambulatory Surgical Centers
Breakup by
Region:
- North America: (United States,
Canada)
- Asia Pacific: (China, Japan, India,
South Korea, Australia, Indonesia, Others)
- Europe: (Germany, France, United
Kingdom, Italy, Spain, Russia, Others)
- Latin America: (Brazil, Mexico,
Others)
- Middle East and Africa
Who are the key players operating in the industry?
The report covers the major market players including:
Bharat Serums and Vaccines Limited (BSV), Boehringer Ingelheim International GmbH, Boston Scientific Corporation, CSL Limited, Haffkine Bio-Pharmaceutical Corporation Limited, Incepta Pharmaceuticals Limited, Merck & Co. Inc., Merck KGaA, MicroPharm Limited, Pfizer Inc., and Rare Disease Therapeutics Inc
If you require any specific information that is not covered currently within the scope of the report, we will provide the same as a part of the customization.
About Us
IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.
IMARC Group’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.
Contact US
IMARC Group
134 N 4th St. Brooklyn, NY 11249, USA
USA: +1-631-791-1145 | Asia: +91-120-433-0800
Email: sales@imarcgroup.com
Follow us on Twitter: @imarcglobal
LinkedIn: https://www.linkedin.com/company/imarc-group/mycompany/
